Effects of a 5‐HT₄ receptor agonist on oesophageal function and gastro‐oesophageal reflux: studies using combined impedance‐manometry and combined impedance‐pH

Abstract

SUMMARYBackground 5-HT 4 receptor agonists are used as promotility agents of the stomach, small and large intestine. There is limited information on the influence of 5-HT 4 receptor agonists on oesophageal function and gastro-oesophageal reflux.

Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives

“…Several studies established that treatment with tegaserod for up to 12 weeks is able to improve constipation and to provide relief of pain/ discomfort and bloating in constipation-predominant IBS [67]. 5-HT4 receptor agonists exert modest but inconsistent effects on esophageal motility and on gastroesophageal reflux in patients with gastroesophageal reflux disease [68]. 5-HT4 agonists do not compare well with the gold standard of therapy for gastroesophageal reflux with a proton pump inhibitor; a place for 5-HT4 agonists in the management of gastroesophageal reflux has therefore not been established.…”

Prospective Assessment of Patient Selection for Antireflux Surgery by Combined Multichannel Intraluminal Impedance pH Monitoring

“…1 Combined multichannel intraluminal impedance-pH monitoring (MII-pH) is able to physically detect each episode of intraesophageal bolus movement, allowing to identify either acid or non-acid reflux episodes and to exactly establish the association of the reflux with symptoms. 2 Since the mechanism of fundoplication is to physically block gastric refluxate to enter into the esophageal lumen by restoring the competence of the lower esophageal sphincter (LES), the routine use of MII-pH in the preoperative evaluation may offer objective parameters for a more accurate indication to surgery. The aim of this study was to verify the efficacy of MII-pH in selecting patients for laparoscopic Nissen fundoplication.…”

Beneficial effect of the 5‐HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study

“…22 Several studies have evaluated the effects of 5-HT 4 agonists on esophageal peristalsis and LES function in non-SSc patients, showing different results. [23][24][25][26][27] However, use of these agents is restricted due to cardiac safety profile issues. Another serotonin receptor agonist, namely the 5-HT1A receptor agonist sumatriptan, may enhance esophageal peristalsis after subcutaneous administration in healthy subjects.…”